Table 2.
Clinical characteristics of patients at baseline and at 6-wk follow-up
| Period; mean ± SD | ||||
|---|---|---|---|---|
|
|
||||
| Characteristic | Baseline (n = 38) | 6-wk follow-up (n = 28) | t value* | p value* |
| Amisulpride, mg | N/A | 262 ± 177 | — | — |
| PANSS positive score | 20.7 ± 3.6 | 14.5 ± 3.9 | 7.04 | < 0.001 |
| PANSS negative score | 22.1 ± 7.6 | 20.1 ± (0.9) | 1.12 | 0.27 |
| PANSS general score | 43.6 ± 7.7 | 33.0 ± 8.6 | 6.79 | < 0.001 |
| PANSS total score | 86.5 ± 14.1 | 67.6 ± 15.8 | 6.17 | < 0.001 |
| Global Assessment of Functioning | 38.9 ± 9.3 | 52.0 ± 11.3 | −5.96 | < 0.001 |
| Calgary Depression Scale for Schizophrenia | 6.9 ± 4.1 | 3.8 ± 3.7 | 4.60 | < 0 0.001 |
| Weight, kg | 76.1 ± 19.9 | 82.0 ± 20.4 | −4.79 | < 0.001 |
PANSS = Positive And Negative Syndrome Scale; SD = standard deviation.
*
Based on paired sample t tests of patients (n = 28), who also participated at follow-up.